✦ LIBER ✦

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer

✍ Scribed by June Koo Lee; Heae Surng Park; Dong-Wan Kim; Kimary Kulig; Tae Min Kim; Se-Hoon Lee; Yoon-Kyung Jeon; Doo Hyun Chung; Dae Seog Heo; Woo-Ho Kim; Yung-Jue Bang

Book ID: 112066993
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 417 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26668

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

369 Timing of responses to crizotinib (P

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

✍ B. Solomon; Y.J. Bang; D.R. Camidge; A.J. Iafrate; E.L. Kwak; R.G. Maki; S.I. Ou 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Favorable response to crizotinib in thre

Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer

✍ Takashi Kijima; Kengo Takeuchi; Satoshi Tetsumoto; Kazuki Shimada; Ryo Takahashi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB

Clinical impact of amphiregulin expressi

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors

✍ Myung Hee Chang; Hee Kyung Ahn; Jeeyun Lee; Chan-Kwon Jung; Yoon-La Choi; Yeon H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 2 views

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB

6570 POSTER Results for progression-free

6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology

✍ Sandler, A.; Reck, M.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB